CoChat
Sign Up
Cited by 162

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects

Kraig, Ellen, Linehan, Leslie A., Liang, Hanyu, Romo, Terry Q., Liu, Qianqian, Wu, Yubo, Benavides, Adriana D., Curiel, Tyler J., Javors, Martin A., Musi, Nicolas, Chiodo, Laura, Koek, Wouter, Gelfond, Jonathan A.L., Kellogg, Dean L.·2018·Experimental Gerontology
DOI 10.1016/j.exger.2017.12.026PMC PMC5869166
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.exger.2017.12.026

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A small, 8-week long randomized clinical trial of 25 older adults between 70 and 95 years of age treated with 1 mg/day of rapamycin experienced more side effects than placebo including a small increase in glycated hemoglobin (within-group p=0.03), and a 40% rise in triglyceride levels (within-group p=0.05).

    “In contrast to the subjects in the above trials, who tolerated everolimus or BEZ235 quite well, a small, 8-week long randomized clinical trial of 25 older adults between 70 and 95 years of age treated with 1 mg/day of rapamycin experienced more side effects than placebo including a small increase in glycated hemoglobin (within-group p=0.03), and a 40% rise in triglyceride levels (within-group p=0.”

    From Targeting the biology of aging with mTOR inhibitors (2023) · cites this paper as [149]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

  • Other parameters of glucose metabolism including insulin sensitivity and pancreatic beta cell function were not affected in the 1 mg/day rapamycin trial.

    “In addition, other parameters of glucose metabolism including insulin sensitivity and pancreatic beta cell function were not affected.”

    From Targeting the biology of aging with mTOR inhibitors (2023) · cites this paper as [149]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 59

  1. Apelo, 2016, Rapamycin: an InhibiTOR of aging emerges from the soil of Easter Island, J. Gerontol. A Biol. Sci. Med. Sci., 71, 841, 10.1093/gerona/glw090 · DOI
  2. Araki, 2011, TOR in the immune system, Curr. Opin. Cell Biol., 23, 1, 10.1016/j.ceb.2011.08.006 · DOI
  3. Barozzi, 2008, Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma, Transplantation, 86, 738, 10.1097/TP.0b013e318184112c · DOI
  4. Basu, 2008, Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin, J. Immunol., 180, 5794, 10.4049/jimmunol.180.9.5794 · DOI
  5. Battaglia, 2006, Rapamycin promotes expansion of functional CD4+ CD25+ FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients, J. Immunol., 177, 8338, 10.4049/jimmunol.177.12.8338 · DOI
  6. Buron, 2013, Profiling sirolimus-induced inflammatory syndrome: a prospective tricentric observational study, PLoS ONE, 8, 10.1371/journal.pone.0053078 · DOI
  7. Chen, 2010, Mammalian target of rapamycin activation underlies HSC defects in autoimmune disease and inflammation in mice, J. Clin. Invest., 120, 4091, 10.1172/JCI43873 · DOI
  8. De Luna-Preitschopf, 2017, Rapamycin maintains the chondrocytic phenotype and interferes with inflammatory cytokine induced processes, Int. J. Mol. Sci., 18, 1494, 10.3390/ijms18071494 · DOI
  9. Delgoffe, 2011, The kinase mTOR regulates the differentiation of helper T cells through the activation of signaling by mTORC1 and mTORC2, Nat. Immunol., 12, 295, 10.1038/ni.2005 · DOI
  10. Demopoulos, 2008, Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials, Transplant. Proc., 40, 1407, 10.1016/j.transproceed.2008.03.084 · DOI
  11. Eiden, 2016, Molecular pathways: increased susceptibilityto infection is a complication of mTOR inhibitor use in cancer therapy, Clin. Cancer Res., 22, 277, 10.1158/1078-0432.CCR-14-3239 · DOI
  12. Fabri, 2011, Role of autophagy in the host response to microbial infection and potential for therapy, Curr. Opin. Immunol., 23, 65, 10.1016/j.coi.2010.10.010 · DOI
  13. Goldberg, 2015, Lifespan extending caloric restriction or mTOR inhibition impair adaptive immunity of old mice by distinct mechanisms, Aging Cell, 14, 130, 10.1111/acel.12280 · DOI
  14. Hayney, 2004, Influenza vaccine antibody responses in lung transplant recipients, Prog. Transplant., 14, 346, 10.1177/152692480401400410 · DOI
  15. He, 2011, Characterization of the metabolic phenotype of rapamycin-treated CD8+ T cells with augmented ability to generate long-lasting memory cells, PLoS ONE, 6
  16. Hurez, 2015, Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune–deficient mice, Aging Cell, 14, 945, 10.1111/acel.12380 · DOI
  17. Jagannath, 2009, Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells, Nat. Med., 15, 267, 10.1038/nm.1928 · DOI
  18. Janes, 2009, Immune regulation by rapamycin: moving beyond T cells, Sci. Signal., 2, 10.1126/scisignal.267pe25 · DOI
  19. Jørgensen, 2001, Sirolimus interferes with the innate response to bacterial products in human whole blood by attenuation of IL-10 production, Scand. J. Immunol., 53, 184, 10.1046/j.1365-3083.2001.00862.x · DOI
  20. Kahana, 2000, Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity, Clin. Transpl., 14, 97, 10.1034/j.1399-0012.2000.140201.x · DOI
  21. Kumar, 2011, Influenza vaccination in the organ transplant recipient: review and summary recommendations, Am. J. Transplant., 11, 2020, 10.1111/j.1600-6143.2011.03753.x · DOI
  22. Lamming, 2013, Young and old genetically heterogeneous HET3 mice on a rapamycin diet are glucose intolerant but insulin sensitive, Aging Cell, 12, 712, 10.1111/acel.12097 · DOI
  23. Lang, 2009, Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement, Transplant. Proc., 41, 4285, 10.1016/j.transproceed.2009.08.050 · DOI
  24. Lesniewski, 2017, Dietary rapamycin supplementation reverses age-related vascular dysfunction and oxidative stress, while modulating nutrient-sensing, cell cycle, and senescence pathways, Aging Cell, 16, 17, 10.1111/acel.12524 · DOI
  25. Lin, 2013, Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer's disease, J. Cereb. Blood Flow Metab., 33, 1412, 10.1038/jcbfm.2013.82 · DOI
  26. Liu, 2010, The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells, Nat. Immunol., 11, 1047, 10.1038/ni.1939 · DOI
  27. Majumder, 2012, Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling, Aging Cell, 11, 326, 10.1111/j.1474-9726.2011.00791.x · DOI
  28. Martell, 1976, Inhibition of the immune response by rapamycin a new antifungal antibiotic, Can. J. Physiol. Pharmacol., 55, 48, 10.1139/y77-007 · DOI
  29. Matsuda, 1999, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp, Diabetes Care, 22, 1462, 10.2337/diacare.22.9.1462 · DOI · Paper page
  30. Miller, 2011, Rapamycin but not resveratrol or simvastatin, extends life span of genetically heterogenous mice, J. Gerontol. A Biol. Sci. Med. Sci., 66, 191, 10.1093/gerona/glq178 · DOI · Paper page
  31. Miller, 2014, Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction, Aging Cell, 13, 468, 10.1111/acel.12194 · DOI
  32. Moes, 2015, Sirolimus and everolimus in kidney transplantation, Drug Discov. Today, 20, 1243, 10.1016/j.drudis.2015.05.006 · DOI
  33. Mushaben, 2011, Rapamycin attenuates airway hyperreactivity, goblet cells, and IgE in experimental asthma, J. Immunol., 187, 5756, 10.4049/jimmunol.1102133 · DOI · Paper page
  34. Nicoletti, 2009, Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin, Clin. Exp. Immunol., 155, 28, 10.1111/j.1365-2249.2008.03780.x · DOI
  35. Ozaki, 2005, Decreased Cytomegalovirus infection after antilymphocyte therapy in sirolimus-treated renal transplant patients, Int. Immunopharmacol., 5, 103, 10.1016/j.intimp.2004.09.008 · DOI
  36. Park, 2012, Destabilization of TNF-α mRNA by rapamycin, Biomol. Ther., 20, 43, 10.4062/biomolther.2012.20.1.043 · DOI
  37. Pavlakis, 2008, Diabetes after transplantation and sirolimus: what's the connection?, J. Am. Soc. Nephrol., 19, 1255, 10.1681/ASN.2008050474 · DOI
  38. Piemonti, 2011, Beta cell function during rapamycin monotherapy in long term type 1 diabetes, Diabetologia, 54, 433, 10.1007/s00125-010-1959-6 · DOI
  39. Ramos-Barron, 2007, Prevention of lupus in NZBxW mice by sirolimus, Lupus, 16, 775, 10.1177/0961203307081401 · DOI
  40. Rao, 2010, Fine-tuning CD8(+) T cell functional responses: mTOR acts as a rheostat for regulating CD8(+) T cell proliferation, survival and differentiation?, Cell Cycle, 9, 2996, 10.4161/cc.9.15.12359 · DOI
  41. Ross, 2015, Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus), Aging, 7, 964, 10.18632/aging.100843 · DOI
  42. Royall, 1992, Bedside assessment of executive cognitive impairment: the executive interview, J. Am. Geriatr. Soc., 40, 1221, 10.1111/j.1532-5415.1992.tb03646.x · DOI
  43. Salehi, 2016, Th1, Th2 and Th17 cytokine profile in patients with multiple sclerosis following treatment with rapamycin, Iran. J. Immunol., 13, 141
  44. Sankhala, 2009, The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents, Target. Oncol., 4, 135, 10.1007/s11523-009-0107-z · DOI
  45. Sofroniadou, 2010, Anaemia, microcytosis and sirolimus—is iron the missing link?, Nephrol. Dial. Transplant., 25, 1667, 10.1093/ndt/gfp674 · DOI
  46. Strauss, 2009, Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin, PLoS ONE, 4, 10.1371/journal.pone.0005994 · DOI
  47. Tang, 2017, A population of innate myelolyphoblastoid effector cell expanded by inactivation of mTOR complex 1 in mice, eLIFE, 6, e32497, 10.7554/eLife.32497 · DOI
  48. Tardif, 2014, Testing efficacy of administration of the antiaging drug rapamycin in a nonhuman primate, the common marmoset, J. Gerontol., 70, 577, 10.1093/gerona/glu101 · DOI
  49. Tariq, 2006, Comparison of the Saint Louis University mental status examination and the mini-mental state examination for detecting dementia and mild neurocognitive disorder-a pilot study, Am. J. Geriatr. Psychiatry, 14, 900, 10.1097/01.JGP.0000221510.33817.86 · DOI · Paper page
  50. Teachey, 2009, Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS), Blood, 108, 1965, 10.1182/blood-2006-01-010124 · DOI
  51. Teachey, 2009, Treatment with sirolimus ameliorates tacrolimus-induced autoimmune cytopenias after solid organ transplant, Pediatr. Blood Cancer, 53, 1114, 10.1002/pbc.22183 · DOI
  52. Thomson, 2009, Immunoregulatory functions of mTOR inhibition, Nat. Rev. Immunol., 9, 324, 10.1038/nri2546 · DOI
  53. Trepanier, 1998, Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update, Clin. Biochem., 31, 345, 10.1016/S0009-9120(98)00048-4 · DOI
  54. Turner, 2011, Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques, Am. J. Transplant., 11, 613, 10.1111/j.1600-6143.2010.03407.x · DOI
  55. Urfer, 2017, A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs, GeroScience, 39, 117, 10.1007/s11357-017-9972-z · DOI · Paper page
  56. Weichhart, 2009, The multiple facets of mTOR in immunity, Trends Immunol., 30, 218, 10.1016/j.it.2009.02.002 · DOI
  57. Wilkinson, 2012, Rapamycin slows aging in mice, Aging Cell, 11, 675, 10.1111/j.1474-9726.2012.00832.x · DOI · Paper page
  58. Willcocks, 2007, The effect of sirolimus therapy on vaccine responses in transplant recipients, Am. J. Transplant., 7, 2006, 10.1111/j.1600-6143.2007.01869.x · DOI
  59. Yard, 1993, CsA, FK506, corticosteroids and rapamycin inhibit TNFα production by cultured PTEC, Kidney Int., 44, 352, 10.1038/ki.1993.251 · DOI

Cited by

Sorted by citations

Metadata

Authors
Kraig, E., Linehan, L. A., Liang, H., Romo, T. Q., Liu, Q., Wu, Y., Benavides, A. D., Curiel, T. J., Javors, M. A., Musi, N., Chiodo, L., Koek, W., Gelfond, J. A. L., & Kellogg, D. L.
Venue
Experimental Gerontology
Publisher
Elsevier BV
Published
2018-05
Volume
105
Pages
53-69
ISSN
0531-5565
DOI
10.1016/j.exger.2017.12.026
PMC
PMC5869166
Cited by
162
References
5
Language
en
Licence
Funders
  • UTHSA IIMS-CTSA (UL1 TR001120)
  • NIDDK (R01-DK80157, R01-DK089229)
  • American Diabetes Association (7-13-GSK-01)
  • San Antonio Claude D. Pepper Older Americans Independence Center (P30 AG044271)
  • San Antonio Nathan Shock Center of Excellence in the Biology of Aging (P30 AG021890)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review